



BioGeneric Pharma S.A.E.



Overview

BioGeneric Pharma “BGP” is an Egyptian private company with multi-national shareholders:

- **Egypt:**
 - Egyptian Private Investors
 - Pharco Corporation “Ranked No. 1 in 2022”
- **Saudi Arabia:**
 - Saudi Private Investors
- **China:**
 - Amotyop Biotech Company “Listed in the Stock Market”
- **USA:**
 - BioGeneric Ltd.

BGP has a newly-established state-of-the-art biopharmaceutical facility specialized in manufacturing of:

- Therapeutic recombinant proteins
- Preventive vaccines

Its main principle activities:

- R&D
- Bio-production
- Analysis
- Commercialization



BGP Production Capabilities

Drug Substance Production Facility:

- Mixers (50 L to 1500 L)
- Tissue culture flasks up to 2000 ml
- Bioreactors from 25 L to 2000 L
- Clarification systems with depth filters up to 20 m²
- Single-use dual chromatography/TFF systems up to 3600 L/h
- Systems for the final drug substance filtration up to 2.0 m²

All equipment operate via single use technology

BSL+2 Quality Control Labs:

- All lab activities are managed by electronic LIMS, ensuring data integrity and audit trails according to CFR- 21 Part 11
- Integrated with electronic QMS & Oracle system managing production & warehouses

BGP Production Capabilities

Formulation & Filling Facilities:

1. Robotic Line (Vial, Cartridges and Pre-filled syringes):

Container	Annual Capacity
PFS	30,144,000
Cartridge	21,888,000
6R Vial	16,128,000
20R Vial	8,480,000
50R Vial	4,480,000

2. Conventional Vial Line:

Container	Annual Capacity
2R Vial	76,800,000
6R Vial	64,000,000
10R Vial	55,296,000
20R Vial	32,832,000
50R Vial	12,288,000



BGP's Portfolio

For IV use after dilution
Each vial contains:
Bevacizumab 100 mg
Excipients:
Trisodium phosphate,
Sodium dihydrogen phosphate monohydrate,
Disodium phosphate anhydrous,
Polysorbate 20,
Water for injection.
Dose & administration:
See package insert.
Store at 2-8 °C
Protect from light
Do not freeze - Do not shake
Keep out of reach of children.

BioBeva 100 mg /
Bevacizumab 4 ml

1 vial of 4 ml of
concentrate for solution
for infusion

100 mg /
4 ml






يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

For IV use after dilution
Each vial contains:
Bevacizumab 400 mg
Excipients:
Trisodium phosphate,
Sodium dihydrogen phosphate monohydrate,
Disodium phosphate anhydrous,
Polysorbate 20,
Water for injection.
Dose & administration:
See package insert.
Store at 2-8 °C
Protect from light
Do not freeze - Do not shake
Keep out of reach of children.

BioBeva 400 mg /
Bevacizumab 16 ml

1 vial of 16 ml of
concentrate for solution
for infusion

400 mg /
16 ml

يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

For IV use after dilution
Each vial contains:
Rituximab 100 mg
Excipients:
Sodium citrate dihydrate,
Polysorbate 80,
Sodium chloride,
Hydrochloric acid q.s. pH 6.5,
Water for injection.
Dose & administration:
See package insert.
Store at 2-8 °C
Protect from light
Do not freeze - Do not shake
Keep out of reach of children.

Rituxigen 100 mg /
Rituximab 10 ml

2 vials of 10 ml of
concentrate for solution
for infusion

100 mg /
10 ml




يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

For IV use after dilution
Each vial contains:
Rituximab 500 mg
Excipients:
Sodium citrate dihydrate,
Polysorbate 80

Rituxigen 500 mg /
Rituximab 50 ml

1 vial of 50 ml of
concentrate for solution
for infusion

500 mg /
50 ml






يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

Each vial contains:
Trastuzumab 150 mg
Excipients:
Histidine hydrochloride monohydrate,
Histidine,
Trisodium dihydrate,
Polysorbate 20
Dose & administration:
See package insert.
Store at 2-8 °C
Protect from light
Do not freeze - Do not shake
Keep out of reach of children.

TrastuThera 150 mg
Trastuzumab 150 mg

1 vial of powder for
concentrate for solution
for I.V. infusion

150 mg

يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

Each vial contains:
Trastuzumab 440 mg
Excipients:
Histidine hydrochloride monohydrate,
Histidine,
Trisodium dihydrate,
Polysorbate 20
Each solvent vial contains:
Benzoyl alcohol
Water for injection
Dose & administration:
See package insert.
Store at 2-8 °C
Protect from light
Do not freeze - Do not shake
Keep out of reach of children.

TrastuThera 440 mg
Trastuzumab 440 mg

1 multi-dose vial powder for
concentrate for solution for I.V. infusion
1 vial of 20 ml bacteriostatic WFI

440 mg




يحفظ في درجة حرارة 2-8 درجة مئوية
يحفظ بعيداً عن الضوء
لا يجمد - لا يهز
يحفظ بعيداً عن متناول الأطفال

BGP and Partners



What does BGP offer?

- CMO/CDMO activities
- Toll Manufacturing
- Out-licensing
- Training
- Upskilling

What is BGP looking for?

- Technology Transfer
- Partnerships
- Financial Projects
- R&D Collaboration
- Joint-venture Projects